Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Document › Details

Boehringer Ingelheim. (9/3/18). "Press Release: Boehringer Ingelheim Biopharmaceuticals China Supports BeiGene in Its China NDA Submission of anti-PD-1 Antibody, Tislelizumab". Shanghai.

Region Region China
Organisations Organisation Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd.
  Group Boehringer Ingelheim (Group)
  Organisation 2 BeiGene (Beijing) Co., Ltd.
Products Product contract manufacturing (biologicals)
  Product 2 tislelizumab (BGB-A317)
Index term Index term BeiGene–Boehringer: biopharmaceuticals, 201801– supply manufacturing of tislelizumab by Boehringer in Shanghai
Person Person Reinig, Matthias (Boehringer Ingelheim 201809 Media + Public Relations)
     


> First biologic manufactured by Boehringer Ingelheim BioChina accepted for New Drug Application review

> Important milestone for Boehringer Ingelheims’ collaboration partner BeiGene in immuno-oncology

> Boehringer Ingelheim BioChina is proud to support BeiGene in serving patients worldwide with this important medicine


BeiGene Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that the National Medical Products Administration of China (NMPA, formerly known as CFDA) for its anti-PD-1 antibody, tislelizumab, for relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL).

Since BeiGene and Boehringer Ingelheim started their collaboration in 2013, Boehringer Ingelheim’s biopharmaceutical contract manufacturing business, known as Boehringer Ingelheim BioXcellence™, has been providing the Chemistry, Manufacturing, and Control (CMC) services for support of the tislelizumab. Boehringer Ingelheim assisted BeiGene with tislelizumab’s development through process and analytical method development, supply of GMP clinical material, and CMC filing support with the NMPA.

Tislelizumab is an investigational anti-PD-1 antibody being studied in a number of malignancies, such as relapsed/refractory classical Hodgkin’s Lymphoma, non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, mature T-and NK-cell lymphomas, and urothelial cancer. Boehringer Ingelheim Biopharmaceuticals (China) Ltd. is committed to providing BeiGene with full contract manufacturing support and supply of tislelizumab at the highest global quality standards to serve patients with this important medicine, if approved.


About Boehringer Ingelheim Biopharmaceuticals China

As one of the world’s largest biopharmaceutical producers, Boehringer Ingelheim is China’s first international provider of biopharmaceutical contract manufacturing solutions with all-round services, including process development, clinical trials and product supply, to its clients in China and all over the world. Boehringer Ingelheim Biopharmaceuticals (China) Ltd.’s facility was officially put into operation in May 2017. As the first and only biopharmaceuticals facility in line with global standards set by a multinational pharma company in China, the facility has become a major milestone in Boehringer Ingelheim’s strategic blueprint for its biopharmaceuticals business globally.


About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.


Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.


Media contact

Matthias Reinig
Media Contact - Corporate Topics
Media + PR
Phone +49 6132 77 184855
Mobile +49 151 15971354
Fax +49 6132 77 6601
› E-mail

Binger Strasse 173
55216 Ingelheim am Rhein GERMANY

   
Record changed: 2018-09-09

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top